BioCentury
ARTICLE | Company News

Medivation neurology, cancer news

April 5, 2010 7:00 AM UTC

Medivation reduced headcount by 23 (20%) to 88 a month after the company's Dimebon latrepirdine missed the co-primary endpoints in a Phase III trial to treat Alzheimer's disease. As a result, Medivat...